Johnson & Johnson Announces that Janssen ’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies

September 3, 2020 -- Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials